UK agency says Pfizer breast cancer drug too expensive

LONDON (Reuters) - Pfizer's breast cancer drug Ibrance, or palbociclib, is too expensive to justify its use on Britain's state-run health service, the country's healthcare cost-effectiveness watchdog said on Friday.

The National Institute for Health and Care Excellence (NICE) said in draft guidance that although the medicine was likely to offer some improvement in overall survival, this could not be quantified from clinical trials.

"Even when allowing for these potential benefits, it was still not enough to make palbociclib cost effective at its current price," Carole Longson, director of NICE's center for health technology assessment, said in a statement on Friday.

Ibrance's list price is 2,950 pounds ($3,700) per 28 days.

Pfizer UK's oncology head David Montgomery noted that the NICE decision was not final decision and said the U.S. drugmaker was committed to working to try and find a solution to make the drug available.

(Reporting by Ben Hirschler, editing by Pritha Sarkar)

Related News

Kuchar leads by one at Scottsdale, Matsuyama lurks

Feb 3, 2017

US-GOLF-PGA:Kuchar leads by one at Scottsdale, Matsuyama lurks

China raises short-term interest rates in fresh...

Feb 3, 2017

US-CHINA-ECONOMY-RATES:China raises short-term interest rates in fresh tightening sign

China tourism revenue up 16 percent over Lunar...

Feb 3, 2017

US-CHINA-TOURISM:China tourism revenue up 16 percent over Lunar New Year

Cardinals ink Martinez to five-year deal

Feb 3, 2017

US-BASEBALL-MLB-STL-MARTINEZ:Cardinals ink Martinez to five-year deal

U.S. transparency reversal stings Canadian,...

Feb 3, 2017

US-USA-RESOURCES-TRANSPARENCY:U.S. transparency reversal stings Canadian, European oil firms

Abe says Japan to show 'unwavering alliance' with...

Feb 3, 2017

US-JAPAN-USA-MATTIS-ABE:Abe says Japan to show 'unwavering alliance' with U.S. under Trump

About Us

In the busy city of New York, News On Express fills you in with all the breaking world news, in short, and brief news articles so that you can read them on-the-go.

Contact us: sales[at]newsonexpress.com

Subscribe Now!